trikafta launch stori set stage
strong
view strong trikafta launch gate order magnitud
consensu expect help perpetu enthusiasm
vrtx commerci execut although expect continu
increas alongsid stock price uniqu high-growth/low-risk
profil among large-cap biotech pipelin option remain
still see room addit appreci rais price target
acceler cf revenu trajectori
strong trikafta launch emblemat favor cf dynam even
exclud sizabl inventori build report demand-
base sale far exceed believ at/near street-
high estim handili beat consensu
cannib vrtx exist cf product particularli symdeko
expect launch clearli appear substanti expand
compani overal revenu opportun q-o-q total cf growth
new het/min pt address increment
revenu benefit switcher
launch may cool bit still gener substanti y-
o-i growth potenti exceed guidanc manag emphas
persistence/compli becom factor launch
progress rapid uptak potenti impact cf treater
capac pt follow-up keep close eye addit
expect gross/net slightli prior estim
may element pent-up demand cannib
cf product like continu nonetheless given run
rate like addit pt growth uk/franc reimburs
vrtx product begin posit impact believ
exceed new guidanc estimate
pipelin progress like increas focu prune
poc data fsg program unlik year expect
focu continu program finer
point readout timelin still ph ii studi
way continu expect base strong preclin data
mechanist rational robust increas key protein biomark
observ early-stag pain drug discontinu
believ remain valu place
pain program learn move forward
ph iii cf studi time
revenu million
valu usd unless otherwis note
price prior trade day market close estimate unless otherwis note
bullish prospect vrtx trikafta come
earli approv particularli concern
long-term threat franchis given high bar
limit potenti competitor believ high-
growth prospect estim ep compound-annual-growth-rate
share bake optim expect
trikafta becom cornerston franchis high
believ given compani strong fundament
addit appreci beyond broader biotech tape
posit leader high-growth high-margin cf space
led kalydeco orkambi symdeko trikafta trikafta
earli approv could support similarli rapid path
eu high bar potenti futur competitor
risk price pressur competit entrant could
outsiz neg impact out-year revenu
competit risk remain maintain
program other target gene therapi approach
difficult improv upon initi data addit triple-
combo result report
potenti catalyst addit updat ex-u
reimburs approv therapi potenti
trikafta approv eu data ph ii
studi aatd
bloomberg capit market estim upside/downside/target
base case assum chanc trikafta expans
europ improv persistence/compli symdeko
continu expans lower age rang
price target deriv dcf analysi discount
rate termin growth rate
success expans trikafta europ better-than-
expect symdeko well ex-u reimburs
price power higher complianc improv would
lead upsid estim upsid scenario
potenti dcf-base valuat would
failur get trikafta approved/reimburs eu
emerg competit reduc long-term market share
erod price power would lead downsid
estim downsid scenario potenti dcf-base
valuat would
exhibit potenti mileston pipelin
producteventtimelinepotenti progress/upd reimburs updat on-going phase studi infant year children cf age ema snda children cf age inhibitor painpotenti updat go-forward molecul indic deuter ivacaftor data ph ii dose-rang once-daili monotherapi on-going ph i/ii ex-u studi on-going ph i/ii ex-u studi sickl cell ph poc studi ph ii proof concept studi ph ii studi ph studi programiniti clinic fibrosi gate residu function mutationsmarketedorkambicyst fibrosi homozygousmarketedtez/iva symdeko/symkevi cystic fibrosi homozygousmarketedtrikafta elexacaftor/tez/iva tripl combin homozyg het/min cf ptsmarket /submit eutrikafta elexacaftor/tez/iva tripl combin homozyg het/min cf ptsphase children corrector homozyg het/min cf ptsphase formerli fibrosi homozyg het/min cf ptsphase corrector homozyg het/min cf ptsphase corrector homozyg het/min cf ptsphase ciliari dyskinesia cfphase merck kgaa solid tumorsphas fibrosisphas small molecul fsgsphase antitrypsin defici phase crispr beta-thalassemia sickl cell diseasephas antitrypsin defici phase inhibitor painphas icrispr/exonicsgen edit dmd partnershipdiabet mellituspreclinicalkymera partnershipsmal molecul protein degrad multipl diseasespreclinicalribometrix inc partnershiprna-target small moleculespreclinicaldrug/target exhibit incom statement
thousand except per share symdeko- probability-weight product revenu total revenu product oper expens incom net pre-tax incom incom attribut non-controlling interest- net incom per share outstand share outstand biotechnolog
price target deriv dcf analysi base busi discount
rate termin growth rate price target support outperform rate
risk rate price target
risk includ lower-than-expect commerci uptak tez/iva price pressur cf
competit emerg safeti issu tripl combo
global biotechnolog compani focus develop
small molecul drug seriou unmet diseas compani previous develop
drug fda approv hiv hep multipl approv drug
includ kalydeco orkambi symdeko treatment variou mutat cystic
fibrosi develop pipelin addit cf drug popul
current drug address addit vertex work build pipelin
beyond cf next year vertex aspir becom fulli integr
biopharmaceut compani discoveri commerci global sale
market commerci infrastructur
